Novavax to Settle Suit Over Covid Vaccine Claims for $47m

Novavax agreed to pay $47 million to settle securities class action filed by Sothinathan Sinnathurai in Nov. 2021.

• Company expects settlement fund will be funded by its directors and officers’ liability insurance
• NOTE: Novavax Faces Shareholder Suit Over Covid-19 Vaccine Claims

To view the source of this information, click here

To contact the reporter on this story:
Lin Cheng in New York at lcheng97@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission.